Nippon Chemiphar Co., Ltd. Financial Summary for the Second Quarter (Interim) of the Fiscal Year Ending March 2027

Overview of Results

For the second quarter of the fiscal year ending March 2027, consolidated net sales were 15,821 million yen, showing almost flat movement year-on-year, while operating loss widened to 6,960 million yen, turning to a deficit. Ordinary income was -684 million yen, and interim net loss attributable to owners of parent expanded to 512 million yen. While sales were maintained mainly in the pharmaceuticals segment, cost increases from yen depreciation and higher R&D expenses for new products and drugs pressured profits. Although the full-year forecast remains unchanged, cash balances have declined.

Outlook and Impact on Shareholders

The full-year performance forecast has not been revised from the previously announced outlook; however, the substantial interim deficit suggests room for financial improvement. Given the potential continuation of reduced cash holdings and rising raw material costs, reviewing cost structure and the pace of new product market introductions will be key. There is no information disclosed regarding direct dividend forecasts for shareholders.